"Now it seems it's all coming around full circle. Increasing APO-A1 and reducing inflammation. Wouldn't it be nice, sweat justice actually if RVX blows the socks off with the results of this BETONMACE trial."

Assuming BETonMACE prevails, it will be interesting to see how Resverlogix and the Clinical Steering Committee spin the apabetalone mechanism of action. The multi-modal MOA may elicit a huge MACE reducing effect. However, the multi-modal MOA also makes it challenging, if not impossible, to ascribe apabetalone's effects to one pathway. The multi-modal MOA includes, but is not limited to, effects on apoAI/HDL, vascular inflammation, complement pathway, acute phase response, coagulation/thrombosis pathway, vascular calcification, glucose metabolism, FMO3 expression/TMAO levels, and kidney function/ALP.

Although associations exist between these individual parameters and CVD risk, very few of these hypotheses have been empirically tested in cardiovascular outcomes trials as an individual variable. The anti-inflammatory hypothesis was successfully shown in the CANTOS trial. Glucose control in diabetics has been proven to provide benefit in some (SGLT2 inhibitors, GLP1-R agonists), but not all, diabetes clinical trials. To the best of my knowledge, the other parameters have never been individually tested in a cardiovascular outcomes trial. 

I wish my time machine worked in the forward direction. Gotta get that fixed. When I do, I'm totally going to name it Sweat Justice, or maybe Sweet Justice. That has a nice ring. LOL.

BearDownAZ (Dr. SnarkyPants is away for the evening)